Fresenius Medical Care shares plummeted 7.1% in European midday trading, wiping out all gains since the start of 2026. This sharp decline follows the company's cautious outlook and underwhelming U.S. performance, which analysts say signals potential headwinds for the global dialysis specialist.

The drop erases significant investor confidence built up over the first months of the year. The weak U.S. results, a key market for Fresenius, suggest challenges in managing costs or capturing growth in a competitive landscape, directly impacting the company's near-term revenue trajectory and market valuation.